AMRA’s Dr. Jennifer Linge will serve as a panelist during a session set as a debate on the potential negative effects of GLP-1-based treatments on muscle in individuals with cardiometabolic diseases at the European Society of Cardiology’s 2025 Meeting.
Medical Research
AMRA Headlines as Lead Partner @ The 3rd Annual Obesity and Weight Loss Drug Development Summit!
📅 SAVE THE DATE: July 14th – 16th, 2025 | Boston, MA LINKÖPING, Sweden, July 3, 2025 – We are absolutely thrilled to join…
AMRA Shares Latest Findings at the FSHD Society’s 2025 International Research Congress
LINKÖPING, Sweden, June 19, 2025 AMRA Medical was thrilled to attend the 2025 International Research Congress, hosted by the FSHD Society! The conference,…
New study shows that six out of ten patients with type 2 diabetes (T2D) had metabolic dysfunction-associated steatotic liver disease (MASLD)
LINKÖPING, Sweden, June 17, 2025 – A newly-published study, led by Mattias Ekstedt’s ectopic fat study group at the Department of Health, Medicine…
Latest Data from SURPASS-3 Trial Gleans Insight Into the Association of Tirzepatide Treatment with Changes in Muscle Composition in Type 2 Diabetes
A recent post-hoc analysis of Lilly’s SURPASS-3 trial unravels the impact of tirzepatide treatment on muscle volume and fat infiltration in individuals with Type 2 Diabetes
Decoding Duchenne Muscular Dystrophy: MRI Study Explores the Relationship Between AMRA’s Muscle Biomarkers and Functional Changes in Individuals with DMD
Recent AMRA research examines whether the use of MRI-based biomarkers as surrogate endpoints in DMD clinical trials is feasible, allowing for more informative descriptions of disease severity and progression in DMD